Addario Lung Cancer Medical Institute - ALCMI

12/14/2025

A new review by Federico Pio Fabrizio in the International Journal of Molecular Sciences MDPI crystallizes an emerging consensus that dormant lung cancer cells are not just quiescent passengers but epigenetically programmed survivors that drive minimal residual disease, therapeutic resistance, and relapse in both SCLC and NSCLC.

Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with tumor recurrence and metastasis posing significant challenges despite advances in targeted therapies and immunotherapy. Cellular dormancy, a reversible, quiescent state marked by cell cycle arrest, has emerged....

12/13/2025

SRSF3 knockdown induces robust, mutation-agnostic cellular senescence in NSCLC models, pointing to a new therapeutic strategy.

12/12/2025

The CONFIRM study delivers compelling evidence that integrating shape-sensing robotic bronchoscopy with mobile cone-beam CT achieves high diagnostic yields for small pulmonary nodules.

12/11/2025

Hackensack Meridian Health's Hennessy Institute and DELFI Diagnostics, backed by an Eli Lilly and Company grant, are investigating whether a blood test can improve adherence to lung cancer screening.

12/10/2025

Congrats to all of the grant recipients! The Lung Cancer Research Foundation (LCRF) has announced its 2025 Scientific Research Grant Awards, committing $1.65 million to eleven new research projects.

/PRNewswire/ -- The Lung Cancer Research Foundation® (LCRF) awarded its annual 2025 Scientific Grant Program awards, funding another $1.65 million in new...

12/09/2025

Mayo Clinic researchers have uncovered why a distinct subset of lung adenocarcinomas mount a strong immune response and respond well to immune checkpoint inhibitors, pinpointing loss of a single tumor‑driving gene, PRKCI, as the key.

12/08/2025

Interesting findings! Turning off ferroptosis suppressor protein 1 (FSP1) can shrink lung adenocarcinoma tumors by up to 80% in vivo, according to new data from NYU Langone Health published in Nature.

Scientists at NYU Langone discovered that blocking a key protein that shields cancer cells from a natural stress-driven death process can dramatically slow lung tumor growth.

12/07/2025

Lung cancer screening by low-dose CT in the US is preventing fewer than one-quarter of the deaths it could, according to new nationally representative modeling from the American Cancer Society.

This study examines the current national prevalence of up-to-date lung cancer screening and estimates lung cancer deaths prevented and life-years gained from screening.

12/06/2025

Universal age-based lung cancer screening from ages 40 to 85 could prevent more than 26,000 additional deaths annually, according to a new JAMA Network Open study from the Northwestern Medicine Canning Thoracic Institute.

12/05/2025

Twenty years ago, there were few options for lung cancer patients. Now, clinicians at Baptist Health Miami Cancer Institute are reporting doubled survival rates driven by advances in robotic surgery and precision oncology.

Twenty years ago, a lung cancer diagnosis offered limited options. Today, survival rates have doubled, and patients are living longer, healthier lives thanks to groundbreaking advances in both surgical techniques and precision medicine.

12/04/2025

Higher glycemic index diets were associated with increased lung cancer risk in a large U.S. cohort, while higher glycemic load was associated with lower risk, according to a new analysis from the National Cancer Institute (NCI) PLCO Screening Trial published in The Annals of Family Medicine.

12/03/2025

REQORSA gene therapy from Genprex, Inc. has reported Acclaim-1 Phase 1 data in Clinical Lung Cancer, showing a clear RP2D, favorable safety, and durable disease control in EGFR-mutant NSCLC progressing on osimertinib.